NEW YORK, May 17, 2021 /PRNewswire/ — Rising prevalence of metastatic melanoma cancer has been witnessed over the years. Verified therapeutics and diagnostics have a positive impact on treating the disease and extending the life span of patients. Improving sophistication in healthcare facilities and technological developments across the world are key factors expanding the market for metastatic melanoma cancer diagnostics. Government initiatives related to creating awareness for early diagnosis and treatment are also expected to drive demand for metastatic melanoma cancer diagnostics.
The global metastatic melanoma cancer diagnostics market is estimated to be valued at US$ 2.9 Bn in 2021, and exhibit a CAGR of close to 8% over the forecast period (2021 – 2031).
Key Takeaways from Market Study
- PET scan test holds the highest value share in market under products, owing to advantages such as it shortens test time and provides accurate attenuation correction and fusion imaging, leading to an increase in diagnostic sensitivity and specificity.
- By service provider, pathology laboratories hold a notable revenue share of more than half in the market.
- Owing to rising cancer cases and increased awareness about cancer screening, the pathology laboratories segment is expected to experience lucrative growth among all service providers at a CAGR of 8.5% through 2031.
- North America accounted for a share of more than 45% in 2020. It is the most lucrative market among all regions…